Even if the post is AI Generated, it does raise a really interesting aspect - the valuation of the Alexion acquisition.
I did not know about Alexion's purchase by Astra Zenica but was intrigued. I asked Gemini to give me a breakdown of the number of drugs that Alexion had/has, the number of conditions it treats, the number of patients for each condition, both in the US and outside the US and also the approximate drug pricing.
It could be wrong but it spat out the following:
| Drug Name | Condition | Estimated Global Patients | US Patients | Total Patients | Price (USD) | Symptoms |
|---|
| 1 | Soliris (eculizumab) | PNH | 10,000 - 15,000 | 6,043 | 18,543 | $400,000 - $700,000 per year | Fatigue, anemia, blood clots, dark urine |
|---|
| 2 | Soliris (eculizumab) | aHUS | 2,000 - 5,000 | 1,000 - 2,500 | 5,250 | $400,000 - $700,000 per year | Kidney failure, low platelet count, hemolytic anemia |
|---|
| 3 | Soliris (eculizumab) | gMG | 20,000 - 40,000 | 10,000 - 20,000 | 45,000 | $400,000 - $700,000 per year | Muscle weakness, fatigue, difficulty swallowing/breathing |
|---|
| 4 | Ultomiris (ravulizumab-cwvz) | PNH | 10,000 - 15,000 | 6,043 | 18,543 | $600,000 per year | Fatigue, anemia, blood clots, dark urine |
|---|
| 5 | Ultomiris (ravulizumab-cwvz) | aHUS | 2,000 - 5,000 | 1,000 - 2,500 | 5,250 | $600,000 per year | Kidney failure, low platelet count, hemolytic anemia |
|---|
| 6 | Ultomiris (ravulizumab-cwvz) | gMG | 20,000 - 40,000 | 10,000 - 20,000 | 45,000 |
|
|
|---|
| 7 | Total | | 92,000 | 75,586 | 137,586 | | |
|---|
It could obviously be wrong and the pricing/numbers could be wrong but if you take it as correct at face value, then I find it very, very interesting and very relevant to Neuren.
Absolutely not arguing that we are worth $39b USD (even though I personally think we are) but I think its interesting to see nonetheless.
(20min delay)